Physician profile
Aviv Katz
NPI 1831344415
$1,701.15
in general payments reported to CMS, 2019-2025
16 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $26.92 · 2021: $272 · 2022: $218 · 2023: $155 · 2024: $195 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.86 | 2019-2024 | Xifaxan |
| Romark Laboratories, Lc | $100.47 | 2019 | |
| Gilead Sciences, INC. | $71.03 | 2019-2025 | |
| Allergan, INC. | $55.85 | 2019 | |
| Janssen Biotech, INC. | $48.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.43 | 2019-2021 | |
| Celgene Corporation | $35.01 | 2023 | Zeposia |
| Genzyme Corporation | $29.08 | 2025 | |
| Pfizer INC. | $28.07 | 2025 | |
| Intercept Pharmaceuticals, INC. | $24.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $20.33 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.58 | 2023 | Linzess |
| Shionogi INC | $16.05 | 2019 | |
| Redhill Biopharma INC. | $13.98 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aviv Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.